Jun 10, 2020 / 03:20PM GMT
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MD
Great. Good afternoon, everybody. Thanks for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs, and we're very pleased to be hosting Johnson & Johnson today at our virtual conference.
Joining us from the company is Jennifer Taubert, who is Executive Vice President and Chairman of Pharmaceuticals. Jennifer, thank you very much for your time today, and thank you for everything that the company is doing to combat COVID. I know you're going to start with some opening remarks before we go into the fireside chat.
Jennifer L. Taubert - Johnson & Johnson - Executive VP & Worldwide Chairman of Pharmaceuticals
Well, thanks, Terence, and good morning to everyone listening in. I'm so glad we found new ways to connect virtually during these unprecedented times, and I'm happy to spend some time with you today to talk about our Pharmaceuticals business.
I'd like to start by acknowledging all those who've been impacted by the recent events in the U.S. as well
Johnson & Johnson at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers